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Background: The novel antidepressant agomelatine, a melatonergic MT1/MT2 agonist combined with 5-HT2c
serotonin antagonist properties, showed antidepressant action in preclinical and clinical studies. There is a general
agreement that the therapeutic action of antidepressants needs the activation of slow-onset adaptations in
downstream signalling pathways finally regulating neuroplasticity. In the last several years, particular attention
was given to cAMP-responsive element binding protein (CREB)-related pathways, since it was shown that chronic
antidepressants increase CREB phosphorylation and transcriptional activity, through the activation of calcium/
calmodulin-dependent (CaM) and mitogen activated protein kinase cascades (MAPK/Erk1/2).
Aim of this work was to analyse possible effects of chronic agomelatine on time-dependent changes of
different intracellular signalling pathways in hippocampus and prefrontal/frontal cortex of male rats. To this
end, measurements were performed 1 h or 16 h after the last agomelatine or vehicle injection.
Results: We have found that in naïve rats chronic agomelatine, contrary to traditional antidepressants, did not
increase CREB phosphorylation, but modulates the time-dependent regulation of MAPK/Erk1/2 and Akt/glycogen
synthase kinase-3 (GSK-3) pathways.
Conclusion: Our results suggest that the intracellular molecular mechanisms modulated by chronic agomelatine
may be partly different from those of traditional antidepressants and involve the time-dependent regulation of
MAPK/Erk1/2 and Akt/GSK-3 signalling pathways. This could exert a role in the antidepressant efficacy of the drug.
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Regulation of gene expression represents a major compo-
nent in the mechanism of action of antidepressants [1-3].
Converging evidence shows that a common target of
chronic antidepressants is a positive modulation of cAMP-
responsive element binding protein (CREB), a transcription
factor that regulates the expression of several genes in-
volved in the control of neuroplasticity, circadian rhythms,
cell survival and cognition [4-9]. CREB transcriptional ac-
tivity is regulated by phosphorylation at Ser133, which is
induced by multiple signalling cascades. In particular, it* Correspondence: daniela.tardito@unimi.it
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unless otherwise stated.was shown that the calcium/calmodulin (CaM)-dependent
and the mitogen activated protein (MAP) kinase cascades
have a crucial role in the activation of CREB consequent to
chronic antidepressant treatments [10-12].
Moreover, recent preclinical biochemical and behav-
ioural evidence suggested an involvement of the Akt/
glycogen synthase kinase-3 (GSK-3) signalling, regulating
gene expression through the activation of CREB and other
transcription factors, both in the modulation of behaviour
and in the mechanism of action of psychoactive drugs
[13-15]. GSK-3 is a Ser/Thr kinase regulated predomin-
antly in an inhibitory manner through phosphorylation at
N-terminal serine residues (Ser21 in GSK-3α and Ser9 in
GSK-3β) by several protein kinases, including Akt [16].
GSK-3β has been linked to bipolar disorder, depression, and
schizophrenia [17-19]. It was recently shown that selective
serotonin reuptake inhibitors (SSRI) and other 5-HT-related
antidepressants (MAO, tricyclic antidepressants) inhibit GSK-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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showed antidepressant-like action in behavioural tests
[22,23]. GSK-3 was also reported to be required for the
rapid antidepressant actions of ketamine [24].
The antidepressant agomelatine is an agonist of melato-
nergic MT1/MT2 receptors and an antagonist of 5-HT2c
receptors. The unique and novel pharmacological profile
of agomelatine has been found to be effective in the treat-
ment of depressive symptoms, with a rapid stabilisation
of circadian rhythms and a favourable tolerability profile.
Efficacy of agomelatine in behavioral tests has been previ-
ously reported in different animal models [25-29]. Thus
far, little is known about the signalling pathways affected
by agomelatine downstream of receptor modulation. This
is especially interesting with regard to the short half-life
(1–2 h) of agomelatine, its mechanism of action and the
signalling pathways responsible for the changes in gene
expression and therapeutic effect.
In this study, we verified whether agomelatine modu-
lates the time-dependent activity of some major signal-
ling pathways known to be regulated by traditional
antidepressants. In particular, the expression and activa-
tion (phosphorylation) of CREB, αCaM kinase II, MAP
kinase/Erk1/2, Akt and GSK-3β were investigated at both
nuclear and cytoplasmic level of hippocampus (HPC)
and prefrontal and frontal cortex (PFC/FC) of rats
treated for three weeks with agomelatine or vehicle and
sacrificed 1 h (6 p.m.) or 16 h (9 a.m.) after the last drug
administration.
We found that agomelatine, rather than potentiating
CREB-related signalling as traditional antidepressants,
was able to partly modulate the time-dependent activa-
tion of the MAP/Erk1/2 and Akt/GSK cascades, suggest-
ing that its antidepressant properties might be related
with a fine-tuning of the time-dependent oscillations in
forebrain intracellular signalling.
Results
Chronic agomelatine does not activate CREB
In order to dissect the effect of chronic agomelatine on
the signalling pathways regulating CREB activity and its
putative time-dependent modulation, rats were chronic-
ally treated with vehicle or agomelatine (once daily
for 21 days) at 5 p.m. and sacrificed after 1 h (6 p.m.) or
16 hours (9 a.m). CREB expression and activation
(phosphorylation at Ser133) were measured in PFC/FC
and HPC nuclear fractions. The two-way ANOVA
highlighted no time-related changes in CREB expression
or phosphorylation levels between 1 h or 16 h post-
treatment and, interestingly, differently from traditional
antidepressants [11], chronic agomelatine did not in-
duce any significant changes in CREB expression or phos-
phorylation (Figure 1A,B for PFC/FC and Figure 2A,B
for HPC).Chronic agomelatine modulates time-dependent changes
of MAPK/Erk1/2 activation in frontal/prefrontal cortex but
not in hippocampus
Different intracellular signalling cascades, including CaM
kinases and MAP kinases, are known to modulate CREB
phosphorylation in the action of antidepressants [10-12].
To investigate whether the lack of CREB activation after
chronic agomelatine was dependent on a lack of activation
or a dysregulation of intracellular signalling cascades regu-
lating CREB phosphorylation, we assessed the expression
and phosphorylation levels of αCaM Kinase II and
MAPK/Erk1/2, in PFC/FC and HPC nuclear fractions fol-
lowing agomelatine treatment.
Interestingly, in both PFC/FC and HPC, we found that
expression and phosphorylation levels of αCaMKII were
unmodified by both time and agomelatine (Figure 1C, D
for PFC/FC; Figure 2C, D for HPC). On the contrary, the
activation of MAPK/Erk1/2, through phosphorylation at
Thr202/Tyr204 residues, was found to be significantly lower
in animals sacrificed in the morning (9 a.m.), than in the
evening (6 p.m.), in nuclei from both PFC/FC (2-way
ANOVA, significant effect of time, pERK1: F(1,26) = 12.88,
p < 0.01; pERK2: F(1,26) = 18.55, p < 0.001) and HPC
(2-way ANOVA: significant effect of time, pERK1: F(1,26) =
28.50, p < 0.0001; pERK2: F(1,26) = 31.72, p < 0.0001)
(Figure 1F,H for PFC/FC; Figure 2F,H for HPC).
Moreover, in PFC/FC, the 2-Way ANOVA highlighted a
significant effect also of treatment for pErk2 (F(1,26) = 4.49,
p < 0.05) (Figure 1H), and the reduction of pErk1 levels at
16 h was significant only for treated rats (Bonferroni post-
hoc test: AGO 16 h vs. 1 h −30.31% p < 0.05) (Figure 1F),
thus suggesting that agomelatine reduces Erk2 activation
and potentiates the time-dependent modulation of pErk1
in PFC/FC. On the contrary, the time-dependent changes
in MAPK/Erk1/2 phosphorylation were similar in HPC of
treated and untreated animals (Figure 2F,H).
Modulation of time-dependent activation of the Akt/GSK-
3 pathway by chronic agomelatine in frontal/prefrontal
cortex and hippocampus
To assess whether agomelatine can modulate the Akt/
GSK-3 signalling pathway, we measured total expression
and phosphorylation levels of Akt and GSK-3β in nu-
clear and cytosolic fractions from PFC/FC and HPC of
rats chronically treated with agomelatine and sacrificed
at 6 p.m. or 9 a.m. As described in details below, al-
though the expression levels of Akt and GSK-3β were
unmodified by chronic agomelatine, the phosphoryl-
ation levels of the kinases were partly and selectively
regulated by the drug, depending on the brain area and
subcellular fraction analysed (Figures 3, 4, 5, 6). Inter-
estingly, in some cases, chronic agomelatine was able to
modulate the activation of Akt/GSK-3 phosphorylation,
as shown below.
Figure 1 (See legend on next page.)
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Figure 1 Time-dependent fluctuation of CREB, αCaM kinase II, MAPK/Erk1/2 in PFC/FC nuclei. Modulation by chronic agomelatine.
Expression levels of CREB (A), αCaM kinase II (C), MAPK/Erk1 (E) and MAPK/Erk2 (G) and phosphorylation levels of CREB at Ser133 (B), αCaM kinase
II at Thr286 (D), MAPK/Erk1 at Thr202/204 (F) and MAPK/Erk2 at Thr202/204 (H) in nuclear fraction of PFC/FC from rats chronically treated with vehicle
(VEH, black bar) or agomelatine (AGO, white bar) and sacrificed 1 or 16 h after the last injection. Data are expressed as % intensity units/mm2
(mean ± S.E.M.). Bonferroni post-hoc test (following 2-way ANOVA): *p < 0.05 VEH treated rats sacrificed 16 h after last injection vs. VEH treated rats
sacrificed 1 h after last injection; § p < 0.05 AGO 16 h after last injection vs. AGO 1 h after last injection; §§p < 0.01 AGO 16 h after last
injection vs. AGO 1 h after last injection (n =8 rats/group).
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showed a significant effect of time on Akt phosphoryl-
ation at Thr308, which is decreased in rats sacrificed in
the morning (F(1,28) = 17.43 p < 0.001) (Figure 3). Interest-
ingly, post-hoc test was significant only for vehicle treated
rats (Bonferroni post-hoc test: VEH 16 h vs. 1 h −33.40%
p < 0.001) (Figure 3B), suggesting that agomelatine dampens
the time-dependent modulation of phospho-Thr308 Akt.
Instead, 2-way ANOVA reported a significant effect of
both time and treatment for phospho-Ser473 Akt, whose
levels were decreased by agomelatine and were signifi-
cantly lower in both groups of animals at 16 h vs 1 h
(2-way ANOVA: time F(1,28) = 21.54 p < 0.0001, treatment
F(1,28) = 5.96 p < 0.05; Bonferroni post-hoc test: VEH 16 h
vs. 1 h −28.81% p < 0.01, AGO 16 h vs. 1 h −29.39%
p < 0.01) (Figure 3C).
A significant effect of time was also found in nuclear
fraction from PFC/FC for phospho-Ser9 GSK-3β, which
levels were lower in both agomelatine and vehicle
treated rats sacrificed in the morning (2-way ANOVA:
time F(1,28) = 22.06 p < 0.0001; Bonferroni post-hoc
tests: VEH 16 h vs. 1 h −13.23% p < 0.01, AGO 16 h vs.
1 h −15.01% p < 0.01) (Figure 3F).
In cytosol from PFC/FC, a significant effect of time was
found on phospho-Ser473 Akt levels (2-way ANOVA: time
F(1,28) = 8.33 p < 0.01), while post-hoc comparisons were
significant only in vehicle treated rats (Bonferroni post-
hoc test: VEH 16 h vs. 1 h −15.44% p < 0.05) (Figure 4C).
Moreover, 2-way ANOVA showed a significant effect of
time on phosphorylation of GSK-3β at Tyr216 (F(1,28) =
12.54 p < 0.01) and the post-hoc test highlighted a signifi-
cant increase at 16 h selectively in rats chronically treated
with agomelatine (Bonferroni post-hoc test: AGO 16 h vs.
1 h +27.33% p < 0.05) (Figure 4E). No significant differ-
ences were found in the phosphorylation state of both
pTyr308 of Akt and pSer9 of Gsk-3β in cytosol from PFC/
FC (Figure 4B and F, respectively).
A different pattern was found in HPC. Indeed, in the
nuclear fraction from HPC, while phospho-Thr308 Akt
levels were similarly reduced in the morning in all ani-
mals (2-way ANOVA: significant effect of time F(1,28) =
21.92 P < 0.0001; Bonferroni post-hoc tests: VEH 16 h
vs. 1 h −29.79% p < 0.01, AGO 16 h vs. 1 h −23.23%
p < 0.05) (Figure 5B), the time-dependent reduction of
phosphorylation of Akt at Ser473 was significant onlyin rats treated with agomelatine (2-way ANOVA: signifi-
cant effect of time F(1,28) = 14.89 p < 0.001; Bonferroni
post-hoc test: AGO 16 h vs. 1 h −27.47% p < 0.01)
(Figure 5C). No differences were found in the phosphor-
ylation state of both pTyr216 and Ser9 of Gsk-3β in HPC
nuclear fraction (Figure 5E and F, respectively).
In the cytosolic fraction from the same area, the
2-way ANOVA highlighted a significant effect of time
for phospho-Thr308 Akt levels (time F(1,28) = 6.19
P < 0.01) (Figure 6B) and of both time and treatment/
time interaction for phospho-Ser473 Akt (time F(1,28) =
8.33 P < 0.01; treatment/time interaction F(1,28) = 4.75
P < 0.05) (Figure 6C), thus suggesting that agomelatine
exerts a different effect at 16 h vs 1 h. Post-hoc test
showed a significant morning decrease of phospho-Thr308
Akt levels only in vehicle, but not in agomelatine treated
rats (Bonferroni post-hoc test: VEH 1 h vs. 16 h −14.30%
p < 0.05) (Figure 6B) and a significant and marked reduction
of phospho-Ser473 Akt levels at 16 h (Bonferroni post-hoc
test: AGO 1 h vs. 16 h −41.12% p < 0.01) (Figure 6C). No
difference was found in GSK-3β phosphorylation at both
Tyr216 and Ser9 residues in HPC cytosol (Figure 6E,F).
For clarity, all significant changes in time-dependent
regulation of MAPK/Erk1/2 and Akt/GSK-3 pathways,
in nuclei and cytosol from PFC/FC and HPC of vehicle
or agomelatine treated rats, and relative statistics are re-
sumed in Table 1.
Discussion
The study of the effects of agomelatine on intracellular sig-
nalling pathways modulating CREB activation demonstrated
that, differently from other antidepressants that activate the
transcription factor CREB, mainly through phosphorylation
by αCaM kinase II and IV and MAPK/Erk1/2 cascades [11],
chronic agomelatine did not act on these molecular mecha-
nisms. Indeed, we did not observe any significant modifica-
tion in both CREB and αCaM kinase II activation in
nuclear fraction from PFC/FC or HPC. Our results are in
line with those of Morley-Fletcher et al. [30], who recently
showed in the same rat strain, that chronic agomelatine, al-
though able to reverse the reduction of CREB phosphoryl-
ation induced by prenatal stress in rats, had no effect on
CREB phosphorylation in non-stressed animals.
A number of previous studies have shown that both acute
and chronic agomelatine increase the expression of brain-
Figure 2 (See legend on next page.)
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Figure 2 Time-dependent fluctuation of CREB, αCaM kinase II, MAPK/Erk1/2 in HPC nuclei. Modulation by chronic agomelatine.
Expression levels of CREB (A), αCaM kinase II (C), MAPK/Erk1 (E) and MAPK/Erk2 (G) and phosphorylation levels of CREB at Ser133 (B), αCaM kinase
II at Thr286 (D), MAPK/Erk1 at Thr202/204 (F) and MAPK/Erk2 at Thr202/204 (H) in nuclear fraction of HPC from rats chronically treated with vehicle
(VEH, black bar) or agomelatine (AGO, white bar) and sacrificed 1 or 16 h after the last injection. Data expressed as above. Statistics as above.
**p < 0.01 VEH 16 h after last injection vs. VEH 1 h after last injection; §§§p < 0.001 AGO 16 h after last injection vs. AGO 1 h after last injection
(n =8 rats/group).
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cules such as fibroblast growth factor, and activity-regulated
cytoskeleton-associated protein [31-35], suggesting that
agomelatine could exert neurotrophic and antidepressant
effects through the activation of molecular mechanisms
partly different from those of other drugs [11,27].
Interestingly, we observed time-dependent changes in
the activation of MAPK/Erk1/2 kinases in both PFC/FC
and HPC. Indeed, we found significantly lower phosphor-
ylation levels of both kinases in animals sacrificed in the
morning as compared to those sacrificed in the evening.
A circadian modulation of MAPK/Erk1/2 activity was re-
cently demonstrated in hippocampus and shown to contrib-
ute to memory consolidation [36-38]. Thus, according to
our present results, time-related fluctuations in nuclear
Erk1/2 activation are present also in PFC/FC, where chronicFigure 3 Time-dependent fluctuation of Akt/GSK-3 signalling pathway
Expression levels of Akt (A) and phosphorylation levels of Akt at Thr308 (B) and
GSK-3 β at Tyr216 (E) and at Ser9 (F) in nuclear fraction of PFC/FC from rats ch
bar) and sacrificed 1 or 16 h after the last injection. Data expressed as above.
VEH 1 h after last injection; §§p <0.01 AGO 16 h after last injection vs. AGO 1treatment with agomelatine seems to partly modulate the
physiological changes. Further studies are needed to better
clarify the circadian nature of these modifications and the
potential of agomelatine in the modulation of the MAPK/
Erk1/2 signalling pathways.
We also observed a time-dependent modulation of
Akt and GSK-3β activation through phosphorylation that
was selectively different depending on the brain area and
the subcellular fraction analysed. In particular, we found
that Akt phosphorylation was lower in PFC/FC and
HPC of animals sacrificed in the morning (16 h after the
last injection). This down-regulation of the kinase activa-
tion is particularly evident in the nuclear fraction, sug-
gesting a possible involvement in the regulation of gene
transcription. Moreover, since the Ser9 of GSK-3β is
phosphorylated by Akt, the reduced phosphorylation ofin PFC/FC nuclear fraction. Modulation by chronic agomelatine.
at Ser473 (C); expression levels of GSK-3 β (D); phosphorylation levels of
ronically treated with vehicle (VEH, black bar) or agomelatine (AGO, white
Statistics as above. **p < 0.01, ***p < 0.001 VEH 16 h after last injection vs.
h after last injection (n =8 rats/group).
Figure 4 Time-dependent fluctuation of Akt/GSK-3 signalling pathway in PFC/FC cytosolic fraction and modulation by chronic
agomelatine. Expression levels of Akt (A) and phosphorylation levels of Akt at Thr308 (B) and at Ser473 (C); expression levels of GSK-3 β (D);
phosphorylation levels of GSK-3 β at Tyr216 (E) and at Ser9 (F) in cytosolic fraction of PFC/FC from rats chronically treated with vehicle (VEH, black
bar) or agomelatine (AGO, white bar) and sacrificed 1 or 16 h after the last injection. Data expressed as above. Statistics as above. *p < 0.05 VEH
16 h after last injection vs. VEH 1 h after last injection; §p < 0.05 AGO 16 h after last injection vs. AGO 1 h after last injection (n =8 rats/group).
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be linked to the morning decrease of Akt activity ob-
served in the same fraction. Although previous studies
have shown a circadian modulation of Akt and GSK-3
activity, the functional role of these fluctuations is poorly
understood. Genetic manipulations, leading to increased
Akt activity in neurons of the suprachiasmatic nucleus,
lengthen the circadian period of locomotor activity,
whereas the reduction of Akt signalling shortens it [39].
Moreover, it was recently demonstrated that both gen-
etic and pharmacological reduction of GSK-3 activity in
mouse embryonic fibroblasts have a specific effect on
the circadian transcriptional oscillation, showing a phase
delay in the transcription of the clock gene mPer2 [40].
Our data suggest that chronic treatment with agomela-
tine reduces phospho-Akt at Ser473 in nuclear fraction of
PFC/FC. More interestingly, chronic agomelatine was
also shown to partly modulate the time-dependent regu-
lation of Akt and GSK-3β activity. Indeed, agomelatine
treatment dampened the morning reduction of Akt
phosphorylation at Thr308 in nuclear fraction and at
Ser473 in cytosol of PFC/FC. Moreover, agomelatine in-
duced a significant increase in pTyr216 GSK-3β in cyto-
sol from PFC/FC and a decrease of pSer473 Akt in nucleifrom HPC 16 h after the last drug injection. Finally, in
the cytosolic fraction from HPC of rats sacrificed in the
morning, agomelatine dampened the phosphorylation
levels of Akt at Thr308 and induced a significant decrease
of pSer473 Akt.
Agomelatine treatment for 21 days was previously de-
scribed to induce an increase in Erk1/2, Akt and GSK-3β
phosphorylation after chronic treatment in whole hippo-
campal extract from HPC of rats sacrificed 16h after last
drug administration [31]. The following factors might
contribute to explaining the apparent contrasting find-
ings compared to our present results: 1- different rat
strains were used, Sprague Dawley rats in our study vs.
Wistar rats in the previous study; 2- different antibodies
were used; 3- the cellular fractions analysed in the two
studies were different (nuclear and cytosol vs total ex-
tract). In this regard, it is well known that the subcellular
distribution and compartmentalization of ERK-MAPKs
between cytosol and nucleus play a key role in the regu-
lation of activity and specificity of the kinases [41,42].
Conclusion
In summary, we have shown that chronic treatment with
the antidepressant agomelatine does not activate CREB
Figure 5 Time-dependent fluctuation of Akt/GSK-3 signalling pathway in HPC nuclear fraction and modulation by chronic agomelatine.
Expression levels of Akt (A) and phosphorylation levels of Akt at Thr308 (B) and at Ser473 (C); expression levels of GSK-3 β (D); phosphorylation levels of
GSK-3 β at Tyr216 (E) and at Ser9 (F) in nuclear fraction of HPC from rats chronically treated with vehicle (VEH, black bar) or agomelatine (AGO, white
bar) and sacrificed 1 or 16 h after the last injection. Data expressed as above. Statistics as above. **p < 0.01 VEH 16 h after last injection vs. VEH 1 h after
last injection; §p < 0.05, §§p < 0.01 AGO 16 h after last injection vs. AGO 1 h after last injection (n =8 rats/group).
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both HPC and PFC/FC of naïve rats. This is of particular
interest because suggests that the antidepressant effect
of agomelatine could be mediated by different molecular
mechanisms with respect to classical antidepressants.
Although further studies are warranted to identify the
different pattern of intracellular signalling pathways
modulated by agomelatine, this difference might contrib-
ute to the therapeutic benefits.
Moreover, although further studies are required to re-
veal whether MAPK/Erk1/2 and Akt/GSK-3 signalling
pathways could play a role in the circadian control in
HPC and PFC/FC, the present work has provided clear
evidence of a time-dependent modulation of these path-
ways in both brain areas. Finally, considering the effects
of agomelatine on the time-dependent regulation of
Erk1/2, Akt and GSK-3β phosphorylation levels, it can
be speculated that this could be a target in the anti-
depressant effect induced by the drug.
Methods
Animals
Twenty-four male Sprague–Dawley rats (175–200 g) were
purchased from Charles River (Calco, Italy). Animals werekept at constant temperature (22°C) with a regular 12 h
light/dark cycle (light-on at 7 a.m.). The rats were housed
in stable groups of four compatible individuals, in 800 cm3
cages, with sawdust bedding, adequate environmental en-
richment and ad libitum access to food and water. The
wellbeing of all animals was daily monitored.
All animal procedures were conducted according to
current regulations for animal experimentation in Italy
(Decreto Legislativo 116/1992) and the European Union
(European Communities Council Directive 2010/63/EU),
were approved by the Italian Ministry of Health (Decreto
Legislativo 295/2012-A) and the whole study adheres to
the ARRIVE guidelines.
Drug treatments
Rats were randomly divided in 4 experimental groups (8
animals each): 1- Chronic vehicle (hydroxyethylcelullose
1%, 1 ml/kg, i.p.) sacrificed 1 h after the last injection;
2- Chronic vehicle sacrificed 16 h after the last injection;
3- Chronic agomelatine (40 mg/kg i.p.) sacrificed 1 h
after the last injection; 4- Chronic agomelatine sacri-
ficed 16 h after the last injection. Treatments were given
once a day for 21 days, at 5.00 p.m. (2 h before the start
of the dark cycle, 7 p.m.) The HPC and PFC/FC were
Figure 6 Time-dependent fluctuation of Akt/GSK-3 signalling pathway in HPC cytosolic fraction and modulation by chronic agomelatine.
Expression levels of Akt (A) and phosphorylation levels of Akt at Thr308 (B) and at Ser473 (C); expression levels of GSK-3 β (D); phosphorylation levels of
GSK-3 β at Tyr216 (E) and at Ser9 (F) in cytosolic fraction of HPC from rats chronically treated with vehicle (VEH, black bar) or agomelatine (AGO, white
bar) and sacrificed 1 or 16 h after the last injection. Data expressed as above. Statistics as above. *p < 0.05 VEH 16 h after last injection vs. VEH 1 h after
last injection; §§p < 0.01 AGO 16h after last injection vs. AGO 1h after last injection (n =8 rats/group).
Musazzi et al. BMC Neuroscience 2014, 15:119 Page 9 of 12
http://www.biomedcentral.com/1471-2202/15/119quickly dissected on ice and processed for subsequent
experiments.
Preparation of subcellular fractions for signalling studies
Individual HPC and PFC/FC were homogenized in 10 vol-
umes of 0.28 M sucrose buffered at pH 7.4 with Tris, con-
taining 20 mM NaF, 5 mM Na2H2P2O7, 1 mM Na3VO4
(protein phosphatase inhibitors), and 2 μl/ml of protease
inhibitor cocktail (Sigma-Aldrich S.r.l., Milan, Italy), using
a glass–teflon tissue grinder (clearance 0.25 mm) in order
to obtain the total homogenate fraction [11]. The hom-
ogenate was further centrifuged (5 min, 1000 g at 4°C)
and the resulting pellet (nuclear fraction) was resuspended
in lysis buffer (120 mM NaCl, 20 mM HEPES pH 7.4,
0.1 mM EGTA, 0.1 mM DTT, containing 20 mM NaF, 5
mM Na2H2P2O7, 1 mM Na3VO4, and 2 μl/ml of protease
inhibitor cocktail). To obtain the cytosolic fraction, the
supernatant of the 1000 g centrifugation was ultracentri-
fuged at 135,000 g for 1 h. Each fraction was immediately
stored at −80°C after being obtained. Protein content of
subcellular fractions was evaluated by using the BCA Pro-
tein Assay (Thermo Fisher Scientific SAS, Illkirch Cedex,
France). Purity of subcellular fractions was checked bymeasuring subcellular distribution of protein markers, as
previously shown [43].
Western blot analysis
Western blot analysis was carried out as previously de-
scribed [11,44], by incubating PVDF membranes, contain-
ing electrophoresed proteins from either nuclear or
cytosolic fractions, with antibodies for CREB (Cat# 9197L
RRID:AB_2245415), phospho-Ser133 CREB (Cat# 9198L
RRID:AB_2085876), p44/42 MAPK (Cat# 9102L RRID:
AB_823494), phospho-p44/42 MAPK (Thr202/Tyr204)
(Cat# 8201S RRID:AB_10695902), Akt (Cat# 9272 RRID:
AB_329827; 1:2000), phospho-Thr308 Akt (Cat# 9275L
RRID:AB_329829) and phospho-Ser473 Akt (Cat# 9271L
RRID:AB_329826), (all from Cell Signalling Technology
Inc, Danvers, MA) (all 1:1000); αCaMKII 1:3000 (Milli-
pore Cat# 05–532 RRID:AB_309787), total GSK-3α and β
(EMD Millipore Cat# MABS77 RRID:AB_11205766;
1:1000), phospho-Tyr216 GSK-3β (EMD Millipore Cat#
05–413 RRID:AB_309721; 1:1000) and phospho-Ser9
GSK-3β (Millipore Cat# 07–835 RRID:AB_2115334;
1:1000) (all from Millipore S.p.A., Vimodrone, Italy),
phospho-Thr286 αCaMKII (Thermo Fisher Scientific Cat#
Table 1 Summarizing significant changes in time-dependent regulation of MAPK/Erk1/2 and Akt/GSK-3 pathways, in
nuclei and cytosol from PFC/FC and HPC of vehicle (VHE) or agomelatine (AGO) treated rats, sacrificed 1 h or 16 h after
last injection
Protein (figure number) Brain area Subcellular fraction Variable F statistic 2 Way ANOVA P value Significant Bonferroni
post-hoc tests
pERK 1 (Figure 1F) PFC/FC nucleus treatment F(1,26) = 1.62 P = 0.2147 AGO 16 h vs.
time F(1,26) = 12.88 P < 0.01 AGO 1 h p < 0.05
interaction F(1,26) = 0.46 P = 0.5042
pERK 2 (Figure 1H) PFC/FC nucleus treatment F(1,26) = 4.49 P < 0.05 AGO 16 h vs.
time F(1,26) = 18.55 P < 0.001 AGO 1 h p < 0.01
interaction F(1,26) = 0.22 P = 0.6401
pERK 1 (Figure 2F) HPC nucleus treatment F(1,26) = 2.45 P = 0.1300 VEH 16 h vs.
time F(1,26) = 28.50 P < 0.0001 VEH 1 h p < 0.01
interaction F(1,26) = 0.13 P = 0.7201 AGO 16 h vs.
AGO 1 h p < 0.001
pERK 2 (Figure 2H) HPC nucleus treatment F(1,26) = 3.24 P = 0.0833 VEH 16 h vs.
time F(1,26) = 31.72 P < 0.0001 VEH 1 h p < 0.01
interaction F(1,26) = 0.11 P = 0.7476 AGO 16 h vs.
AGO 1 h p < 0.001
pThr308 Akt (Figure 3B) PFC/FC nucleus treatment F(1,28) = 0.61 P = 0.4429 VEH 16 h vs.
time F(1,28) = 17.43 P < 0.001 VEH 1 h p < 0.001
interaction F(1,28) = 2.00 P = 0.1685
pSer473 Akt (Figure 3C) PFC/FC nucleus treatment F(1,28) = 5.96 P < 0.05 VEH 16 h vs.
time F(1,28) = 21.54 P < 0.0001 VEH 1 h p < 0.01
interaction F(1,28) = 0.00 P = 0.9631 AGO 16 h vs.
AGO 1 h p < 0.01
pSer9 GSK-3 β (Figure 3F) PFC/FC nucleus treatment F(1,28) = 0.00 P = 0.9779 VEH 16 h vs.
time F(1,28) = 22.06 P < 0.0001 VEH 1 h p < 0.01
interaction F(1,28) = 0.09 P = 0.7695 AGO 16 h vs.
AGO 1 h p < 0.01
pSer473 Akt (Figure 4C) PFC/FC cytosol treatment F(1,28) = 4.15 P = 0.0512 VEH 16 h vs.
time F(1,28) = 8.33 P < 0.01 VEH 1 h p < 0.05
interaction F(1,28) = 0.22 P = 0.6429
pTyr216 GSK-3 β (Figure 4E) PFC/FC cytosol treatment F(1,28) = 2.87 P = 0.1016 AGO 16 h vs.
time F(1,28) = 12.54 P < 0.05 AGO 1 h p < 0.05
interaction F(1,28) = 0.25 P = 0.6183
pThr308 Akt (Figure 5B) HPC nucleus treatment F(1,28) = 0.46 P = 0.5017 VEH 16 h vs.
time F(1,28) = 21.92 P < 0.0001 VEH 1 h p < 0.01
interaction F(1,28) = 0.34 P = 0.5669 AGO 16 h vs.
AGO 1 h p < 0.05
pSer473 Akt (Figure 5C) HPC nucleus treatment F(1,28) = 0.86 P = 0.3626 AGO 16 h vs.
time F(1,28) = 14.89 P < 0.001 AGO 1 h p < 0.01
interaction F(1,28) = 0.29 P = 0.5928
Akt tot (Figure 6A) HPC cytosol treatment F(1,28) = 0.30 P = 0.5863 -
time F(1,28) = 6.19 P < 0.05
interaction F(1,28) = 0.18 P = 0.6777
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Table 1 Summarizing significant changes in time-dependent regulation of MAPK/Erk1/2 and Akt/GSK-3 pathways, in
nuclei and cytosol from PFC/FC and HPC of vehicle (VHE) or agomelatine (AGO) treated rats, sacrificed 1 h or 16 h after
last injection (Continued)
pThr308 Akt (Figure 6B) HPC cytosol treatment F(1,28) = 1.34 P = 0.2567 VEH 16 h vs.
time F(1,28) = 9.61 P < 0.01 VEH 1 h p < 0.05
interaction F(1,28) = 0.22 P = 0.6447
pSer473 Akt (Figure 6C) HPC cytosol treatment F(1,28) = 0.52 P = 0.4788 AGO 16 h vs.
time F(1,28) = 8.33 P < 0.01 AGO 1 h p < 0.01
interaction F(1,28) = 4.75 P < 0.05
Significant effects are highlighted in bold.
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(Sigma-Aldrich Cat# A1978 RRID:AB_476692). Following
incubation with peroxidase-coupled secondary antibodies,
protein bands were detected by using ECL (GE Healthcare
Europe GmbH, Milano, Italy). All protein bands used were
within linear range of standard curves, and both total ex-
pression and phosphorylation levels were normalized for
β-actin level in the same membrane. Standardization and
quantitation were performed with Quantity One software
(BioRad Laboratories S.r.l., Segrate, Italy).Statistical analysis
Two-way ANOVA was employed for the analysis of the
experiments, with treatment and time from the last ad-
ministration as independent factors. When appropriate,
further differences were analyzed by Bonferroni post-hoc
test. Significance was assumed at p < 0.05. Statistical ana-
lysis of the data was carried out using GraphPad Prism4
(GraphPad Software Inc., USA). For the sake of simpli-
city in the graphs were reported only the significant
Bonferroni post-hoc comparisons’ p values; the complete
results of the 2-way ANOVA are described in the text.
Data are presented as means ± standard error (SEM),
with each individual group composed of 8 samples. For
graphic clarity, optical densities from experimental
groups were expressed and presented as a mean percent-
age of the vehicle treated group.
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